ACR-2316 for Cancer

Phase 1

Recruiting

Research Sponsored by Acrivon Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months

Must have progressed after prior line of treatment

Must not have

Participants with known symptomatic brain metastases

Women who are pregnant or lactating

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pharmacokinetic (pk) testing in cycle 1, 2 & 3 (each cycle is 21 days). predose and multiple time points after dose up to cycle 3.

Awards & highlights

No Placebo-Only Group

Summary

This trial is the first time ACR-2316 is being tested in humans to see if it is safe for treating patients with certain types of advanced or spreading solid tumors.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am mostly active and my doctor thinks I have at least 3 months to live.

Select...

My condition worsened after my last treatment.

Select...

My cancer is confirmed to be advanced and has spread.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have brain metastases that cause symptoms.

Select...

I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pharmacokinetic (pk) testing in cycle 1, 2 & 3 (each cycle is 21 days). predose and multiple time points after dose up to cycle 3.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pharmacokinetic (pk) testing in cycle 1, 2 & 3 (each cycle is 21 days). predose and multiple time points after dose up to cycle 3.

This trial's timeline: 3 weeks for screening, Varies for treatment, and pharmacokinetic (pk) testing in cycle 1, 2 & 3 (each cycle is 21 days). predose and multiple time points after dose up to cycle 3. for reporting.